European regulators have granted Johnson & Johnson company Cerenovus CE mark approval for its Bravo blood flow diverter for use in the treatment of complex aneurysm. The device is indicated for diverting blood flow from the aneurysm site to treat patients with intracranial aneurysms.
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.